Gut Pharmacomicrobiomics: The tip of an iceberg of complex interactions between drugs and gut-associated microbes

Gut Pathogens

Volumn 4, Issue 1, 2012, Pages

  Saad, Rama ^a,b   Rizkallah, Mariam R ^a,b   Aziz, Ramy K ^a,c,d  

^a Egyptian Bioinformatics and Systems Biology Network (EgyBionet)   (Egypt)

^b AMERICAN UNIVERSITY IN CAIRO   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Human microbiome project; Liver enzymes; Metabolomics; Metabonomics; Metagenome; Microbiota; Pharmacodynamics; Pharmacokinetics; Pharmacomicrobiomics; Xenobitoics

Indexed keywords

EID: 84871538443     PISSN: None     EISSN: 17574749     Source Type: Journal    
DOI: 10.1186/1757-4749-4-16     Document Type: Review

References (73)

1. Structure, function and diversity of the healthy human microbiome. Human Microbiome Project Consortium, Nature 2012 486 207 214 10.1038/nature11234 22699609
2. Microbial ecology of the gastrointestinal tract. Savage DC, Annu Rev Microbiol 1977 31 107 133 10.1146/annurev.mi.31.100177.000543 334036
3. The NIH Human Microbiome Project. Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, et al. Genome Res 2009 19 2317 2323 19819907
4. Tackling the microbiome. Hood L, Science 2012 336 1209 10.1126/science.1225475 22674329
5. Metabolism of drugs by microorganisms in the intestine. Goldman P, Peppercorn MA, Goldin BR, Am J Clin Nutr 1974 27 1348 1355 4155602
6. The bacterial degradation of chloramphenicol. Holt R, Lancet 1967 1 1259 1260 4165044
7. Role of intestinal microorganisms in determining cycasin toxicity. Spatz M, Smith DW, McDaniel EG, Laqueur GL, Proc Soc Exp Biol Med 1967 124 691 697 4960684
8. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR, N Engl J Med 1981 305 789 794 10.1056/NEJM198110013051403 7266632 (Pubitemid 11007233)
9. Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. Mathan VI, Wiederman J, Dobkin JF, Lindenbaum J, Gut 1989 30 971 977 10.1136/gut.30.7.971 2759492 (Pubitemid 19187939)
10. Gut microorganisms, mammalian metabolism and personalized health care. Nicholson JK, Holmes E, Wilson ID, Nat Rev Microbiol 2005 3 431 438 10.1038/nrmicro1152 15821725 (Pubitemid 40590386)
11. The gastrointestinal microbiota as a site for the biotransformation of drugs. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW, Int J Pharm 2008 363 1 25 10.1016/j.ijpharm.2008.07.009 18682282
12. Xenobiotic metabolomics: major impact on the metabolome. Johnson CH, Patterson AD, Idle JR, Gonzalez FJ, Annu Rev Pharmacol Toxicol 2012 52 37 56 10.1146/annurev-pharmtox-010611-134748 21819238
13. Acetamide-a metabolite of metronidazole formed by the intestinal flora. Koch RL, Chrystal EJ, Beaulieu BB Jr, Goldman P, Biochem Pharmacol 1979 28 3611 3615 10.1016/0006-2952(79)90407-6 231450 (Pubitemid 10177020)
14. Metagenomics: genomic analysis of microbial communities. Riesenfeld CS, Schloss PD, Handelsman J, Annu Rev Genet 2004 38 525 552 10.1146/annurev.genet. 38.072902.091216 15568985 (Pubitemid 40013737)
15. Viral metagenomics. Edwards RA, Rohwer F, Nat Rev Microbiol 2005 3 504 510 10.1038/nrmicro1163 15886693 (Pubitemid 40716177)
16. Developing a metagenomic view of xenobiotic metabolism. Haiser HJ, Turnbaugh PJ, Pharmacol Res 2012 10.1016/j.phrs.2012.07.009
17. The Human Microbiome Project, personalized medicine and the birth of pharmacomicrobiomics. Rizkallah MR, Saad R, Aziz RK, Curr Pharmacogenomics Person Med 2010 8 182 193
18. Rethinking pharmacogenomics in an ecosystem: drug-microbiome interactions, pharmacomicrobiomics, and personalized medicine for the human supraorganism. Aziz RK, Curr Pharmacogenomics Person Med 2012 10 258 261
19. PharmacoMicrobiomics or how bugs modulate drugs: an educational initiative to explore the effects of human microbiome on drugs. Aziz RK, Saad R, Rizkallah MR, BMC Bioinforma 2011 12 10
20. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Wilson ID, Proc Natl Acad Sci USA 2009 106 14187 14188 19706501
21. New technologies, human-microbe interactions, and the search for previously unrecognized pathogens. Relman DA, J Infect Dis 2002 186 Suppl 2 254 S258 12424706 (Pubitemid 35370490)
22. The host-microbe interface within the gut. Shanahan F, Best Pract Res Clin Gastroenterol 2002 16 915 931 10.1053/bega.2002.0342 12473298
23. Meeting report: the terabase metagenomics workshop and the vision of an Earth microbiome project. Gilbert JA, Meyer F, Antonopoulos D, Balaji P, Brown CT, Desai N, Eisen JA, Evers D, Field D, Feng W, et al. Stand Genomic Sci 2010 3 243 248 10.4056/sigs.1433550 21304727
24. Beyond diversity: functional microbiomics of the human colon. Egert M, de Graaf AA, Smidt H, de Vos WM, Venema K, Trends Microbiol 2006 14 86 91 10.1016/j.tim.2005.12.007 16406528 (Pubitemid 43190738)
25. The business of pharmacogenomics. Persidis A, Nat Biotechnol 1998 16 209 210 10.1038/nbt0298-209 9487533 (Pubitemid 28078513)
26. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nicholson JK, Wilson ID, Nat Rev Drug Discov 2003 2 668 676 10.1038/nrd1157 12904817 (Pubitemid 37361770)
27. A meta-metabolome network of carbohydrate metabolism: Interactions between gut microbiota and host. Ibrahim M, Anishetty S, Biochem Biophys Res Commun 2012 428 2 278 284 10.1016/j.bbrc.2012.10.045 23085046
28. Impact of gut microbiota on intestinal and hepatic levels of phase 2 xenobiotic-metabolizing enzymes in the rat. Meinl W, Sczesny S, Brigelius-Flohe R, Blaut M, Glatt H, Drug Metab Dispos 2009 37 1179 1186 10.1124/dmd.108.025916 19282396
29. Mutagen excretion and cytochrome P-450-dependent activity in germfree and conventional rats fed a diet containing fried meat. Overvik E, Lindeskog P, Midtvedt T, Gustafsson JA, Food Chem Toxicol 1990 28 253 261 10.1016/0278-6915(90)90037-N 2358251 (Pubitemid 20184096)
30. Carcinogenicity of food mutagens. Sugimura T, Nagao M, Wakabayashi K, Environ Health Perspect 1996 104 Suppl 3 429 433 10.1289/ehp.96104s3429 8781358 (Pubitemid 26196381)
31. Interactions of the gut microflora and the host in toxicology. Rowland IR, Toxicol Pathol 1988 16 147 153 10.1177/019262338801600207 3055224
32. The human colonic microflora influences the alterations of xenobiotic-metabolizing enzymes by catechins in male F344 rats. Lhoste EF, Ouriet V, Bruel S, Flinois JP, Brezillon C, Magdalou J, Cheze C, Nugon-Baudon L, Food Chem Toxicol 2003 41 695 702 10.1016/S0278-6915(03)00010-3 12659723 (Pubitemid 36349551)
33. Formation of catechol estrogens by intestinal bacterial demethylation of 2-methoxyestrone. Axelson M, Sjovall J, Biochim Biophys Acta 1983 751 162 165 10.1016/0005-2760(83)90170-4 6299367 (Pubitemid 13101013)
34. Chlorogenic acid bioavailability largely depends on its metabolism by the gut microflora in rats. Gonthier MP, Verny MA, Besson C, Remesy C, Scalbert A, J Nutr 2003 133 1853 1859 12771329 (Pubitemid 36666525)
35. Directly coupled high-performance liquid chromatography and nuclear magnetic resonance spectroscopic with chemometric studies on metabolic variation in Sprague-Dawley rats. Gavaghan CL, Nicholson JK, Connor SC, Wilson ID, Wright B, Holmes E, Anal Biochem 2001 291 245 252 10.1006/abio.2000.5034 11401298 (Pubitemid 32373159)
36. Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Bowey E, Adlercreutz H, Rowland I, Food Chem Toxicol 2003 41 631 636 10.1016/S0278-6915(02)00324-1 12659715 (Pubitemid 36349543)
37. Interindividual differences in microbial counts and biochemical- associated variables in the feces of healthy Spanish adults. Delgado S, Ruas-Madiedo P, Suarez A, Mayo B, Dig Dis Sci 2006 51 737 743 10.1007/s10620-006-3200-5 16614997
38. Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. Akao T, Kawabata K, Yanagisawa E, Ishihara K, Mizuhara Y, Wakui Y, Sakashita Y, Kobashi K, J Pharm Pharmacol 2000 52 1563 1568 11197087 (Pubitemid 32058657)
39. Interaction between phenolics and gut microbiota: role in human health. Selma MV, Espin JC, Tomas-Barberan FA, J Agric Food Chem 2009 57 6485 6501 10.1021/jf902107d 19580283
40. PubChem: integrated platform of small molecules and biological activities. Bolton EE, Wang Y, Thiessen PA, Bryant SH, Annu Rep Comput Chem 2008 4 217 241
41. The Human Microbiome Project in 2011 and beyond. Proctor LM, Cell Host Microbe 2011 10 287 291 10.1016/j.chom.2011.10.001 22018227
42. A human gut microbial gene catalogue established by metagenomic sequencing. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al. Nature 2010 464 59 65 10.1038/nature08821 20203603
43. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK, Proc Natl Acad Sci USA 2009 106 14728 14733 10.1073/pnas.0904489106 19667173
44. An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora. Vermes A, Kuijper EJ, Guchelaar HJ, Dankert J, Chemotherapy 2003 49 17 23 10.1159/000069784 12714804 (Pubitemid 36469790)
45. The gut microbiome and pre-systemic metabolism: current state and evolving research. Grundmann O, J Drug Metab Toxicol 2010 1 105
46. Bacteroides fragilis RecA protein overexpression causes resistance to metronidazole. Steffens LS, Nicholson S, Paul LV, Nord CE, Patrick S, Abratt VR, Res Microbiol 2010 161 346 354 10.1016/j.resmic.2010.04.003 20435137
47. The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Strong HA, Renwick AG, George CF, Liu YF, Hill MJ, Xenobiotica 1987 17 685 696 10.3109/00498258709043976 3630204 (Pubitemid 17121204)
48. Sulindac metabolism: the importance of an intact colon. Strong HA, Warner NJ, Renwick AG, George CF, Clin Pharmacol Ther 1985 38 387 393 10.1038/clpt.1985.192 4042521 (Pubitemid 16250311)
49. Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2- bromovinyl)uracil in rats. Ashida N, Ijichi K, Watanabe Y, Machida H, Biochem Pharmacol 1993 46 2201 2207 10.1016/0006-2952(93)90610-9 8274153 (Pubitemid 24012312)
50. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Nakayama H, Kinouchi T, Kataoka K, Akimoto S, Matsuda Y, Ohnishi Y, Pharmacogenetics 1997 7 35 43 10.1097/00008571-199702000- 00005 9110360 (Pubitemid 27153317)
51. The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. Kitamura S, Sugihara K, Kuwasako M, Tatsumi K, J Pharm Pharmacol 1997 49 253 256 9231340 (Pubitemid 27197008)
52. The subsystems approach to genome annotation and its use in the project to annotate 1000 genomes. Overbeek R, Begley T, Butler RM, Choudhuri JV, Chuang HY, Cohoon M, de Crecy-Lagard V, Diaz N, Disz T, Edwards R, et al. Nucleic Acids Res 2005 33 5691 5702 10.1093/nar/gki866 16214803 (Pubitemid 41548835)
53. Correlation between protein and mRNA abundance in yeast. Gygi SP, Rochon Y, Franza BR, Aebersold R, Mol Cell Biol 1999 19 1720 1730 10022859 (Pubitemid 29098230)
54. Correlations between RNA and protein expression profiles in 23 human cell lines. Gry M, Rimini R, Stromberg S, Asplund A, Ponten F, Uhlen M, Nilsson P, BMC Genomics 2009 10 365 10.1186/1471-2164-10-365 19660143
55. A road map for the development of community systems (CoSy) biology. Zengler K, Palsson BO, Nat Rev Microbiol 2012 10 366 372 22450377
56. A systems biology approach to studying the role of microbes in human health. Thiele I, Heinken A, Fleming RM, Curr Opin Biotechnol 2012
57. First-pass effect: significance of the intestine for absorption and metabolism. Doherty MM, Pang KS, Drug Chem Toxicol 1997 20 329 344 10.3109/01480549709003891 9433662 (Pubitemid 28078544)
58. The Human Variome Project (HVP) 2009 Forum Towards Establishing Standards Howard HJ, Horaitis O, Cotton RG, Vihinen M, Dalgleish R, Robinson P, Brookes AJ, Axton M, Hoffmann R, Tuffery-Giraud S, Hum Mutat 2010 31 366 367 10.1002/humu.21175 20052753
59. The International HapMap Project. International HapMap Consortium, Nature 2003 426 789 796 10.1038/nature02168 14685227 (Pubitemid 38056856)
60. The metagenomics RAST server-a public resource for the automatic phylogenetic and functional analysis of metagenomes. Meyer F, Paarmann D, D'Souza M, Olson R, Glass EM, Kubal M, Paczian T, Rodriguez A, Stevens R, Wilke A, et al. BMC Bioinforma 2008 9 386 10.1186/1471-2105-9-386
61. SEED Servers: high-performance access to the SEED genomes, annotations, and metabolic models. Aziz RK, Devoid S, Disz T, Edwards RA, Henry CS, Olsen GJ, Olson R, Overbeek R, Parrello B, Pusch GD, et al. PLoS One 2012 7 48053 10.1371/journal.pone.0048053 23110173
62. PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Owen RP, Altman RB, Klein TE, Hum Mutat 2008 29 456 460 10.1002/humu.20731 18330919 (Pubitemid 351536983)
63. PACdb: a database for cell-based pharmacogenomics. Gamazon ER, Duan S, Zhang W, Huang RS, Kistner EO, Dolan ME, Cox NJ, Pharmacogenet Genomics 2010 20 269 273 20216476
64. The Comparative Toxicogenomics Database facilitates identification and understanding of chemical-gene-disease associations: arsenic as a case study. Davis AP, Murphy CG, Rosenstein MC, Wiegers TC, Mattingly CJ, BMC Med Genomics 2008 1 48 10.1186/1755-8794-1-48 18845002
65. The pharmacomicrobiomics portal: a database for drug-microbiome interactions. Rizkallah MR SG-E, Saad R, Aziz RK, Curr Pharmacogenomics Person Med 2012 10 195 203 10.2174/187569212802510030
66. KEGG: Kyoto encyclopedia of genes and genomes. Kanehisa M, Goto S, Nucleic Acids Res 2000 28 27 30 10.1093/nar/28.1.27 10592173 (Pubitemid 30047706)
67. High-throughput generation, optimization and analysis of genome-scale metabolic models. Henry CS, DeJongh M, Best AA, Frybarger PM, Linsay B, Stevens RL, Nat Biotechnol 2010 28 977 982 10.1038/nbt.1672 20802497
68. BRENDA, the enzyme information system in 2011. Scheer M, Grote A, Chang A, Schomburg I, Munaretto C, Rother M, Sohngen C, Stelzer M, Thiele J, Schomburg D, Nucleic Acids Res 2011 39 670 D676 10.1093/nar/gkq1089 21062828
69. Human Variome Project: an international collaboration to catalogue human genetic variation. Ring HZ, Kwok PY, Cotton RG, Pharmacogenomics 2006 7 969 972 10.2217/14622416.7.7.969 17054407 (Pubitemid 44644777)
70. Towards an ecology of collective innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA). Ozdemir V, Rosenblatt DS, Warnich L, Srivastava S, Tadmouri GO, Aziz RK, Reddy PJ, Manamperi A, Dove ES, Joly Y, et al. Curr Pharmacogenomics Person Med 2011 9 243 251 22523528
71. The Genomes OnLine Database (GOLD) v.4: status of genomic and metagenomic projects and their associated metadata. Pagani I, Liolios K, Jansson J, Chen IM, Smirnova T, Nosrat B, Markowitz VM, Kyrpides NC, Nucleic Acids Res 2012 40 571 579 10.1093/nar/gkr1100
72. Systems-level characterization of a host-microbe metabolic symbiosis in the mammalian gut. Heinken A, Sahoo S, Fleming RM, Thiele I, Gut Microbes 2013 4 1 13
73. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S, Inflamm Bowel Dis 2007 13 372 379 10.1002/ibd.20024 17206723 (Pubitemid 46668240)